^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GS-4528

    i
    Other names: GS-4528
    Associations

    News

    Trials
    Company:
    Gilead
    Drug class:
    IL-2 stimulant
    Related drugs:
    Associations

    News

    Trials
    4d
    Machine learning-based identification of core regulatory genes in hepatocellular carcinoma: insights from lactylation modification and liver regeneration-related genes. (PubMed, Front Oncol)
    We integrated lactylation modification profiles with transcriptomic data from three murine liver regeneration datasets (GSE20426, GSE70593, GSE4528)...This work uniquely establishes lactylation as a metabolic-epigenetic bridge linking physiological regenerative pathways to oncogenesis. By leveraging liver regeneration models and machine learning, we propose the identified gene panel as dual-purpose biomarkers for HCC diagnosis and therapeutic targeting, offering new insights into the metabolic-epigenetic regulation of HCC.
    Journal
    |
    CD8 (cluster of differentiation 8) • CCNA2 (Cyclin A2) • KIF2C (Kinesin Family Member 2C) • RACGAP1 (Rac GTPase activating protein 1)
    |
    GS-4528
    3ms
    Study of GS-4528 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=182, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Yutuo (zimberelimab) • GS-4528
    1year
    Study of GS-4528 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=182, Recruiting, Gilead Sciences | N=132 --> 182
    Enrollment change • Combination therapy • Metastases
    |
    Yutuo (zimberelimab) • GS-4528
    over2years
    Study of GS-4528 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=132, Recruiting, Gilead Sciences | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Yutuo (zimberelimab) • GS-4528